Belzutifan for Cancer

This trial tests a new treatment called belzutifan for certain rare cancers. It aims to determine belzutifan's safety and patient tolerance. The trial focuses on three types of tumors: rare adrenal gland tumors, digestive tract tumors without common gene changes, and tumors linked to Von Hippel-Lindau disease. Individuals with these specific tumors that have spread locally or to other parts of the body might be suitable for this study. As a Phase 2 trial, it measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important research.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that belzutifan is generally well-tolerated by patients. Common side effects include low red blood cell count (anemia), tiredness, and headaches. These findings come from studies involving patients with Von Hippel-Lindau disease who used this treatment.

The studies did not identify any new or unexpected safety issues, suggesting that the treatment is relatively safe. However, while most side effects can be managed, more research is needed to fully understand the drug's safety.

Belzutifan is unique because it targets the HIF-2α protein, a factor that promotes tumor growth, which is different from many current cancer treatments that primarily focus on inhibiting other pathways. This new mechanism of action is especially promising because it offers a fresh approach to tackling cancer cells that might be resistant to existing therapies. Researchers are excited about belzutifan because it has the potential to be effective in patients who have not responded well to standard treatments like chemotherapy, targeted therapies, or immunotherapies.

Research has shown that belzutifan effectively treats tumors linked to Von Hippel-Lindau (VHL) disease. Studies have found that up to 70% of VHL patients experience tumor shrinkage. For those with VHL-related kidney cancer, belzutifan prolongs the period before the cancer worsens. This treatment blocks a protein that promotes tumor growth, potentially slowing or stopping the disease. Although limited information exists on its use for other cancers like pheochromocytoma/paraganglioma (PPGL) and wild-type gastrointestinal stromal tumors (wtGIST), the positive results in VHL-related tumors offer hope. Participants in this trial will receive belzutifan to further evaluate its effectiveness across different cancer types.⁵⁶⁷⁸⁹